An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...
The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...
Dr. Ashkan Emadi, principal investigator of a first-in-world phase 2 clinical trial evaluating subcutaneous Blincyto (blinatumomab) for CD19-positive mixed phenotype acute leukemia, sat down for an ...
FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
2d
Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline
Current quarter guidance for 2026 total revenue of $1.71 billion to $1.81 billion and non-GAAP diluted EPS of $7.75 to $8.25 marks a substantial increase from the previous quarter's guidance of $1.3 ...
Halozyme Therapeutics has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio and its subcutaneous injection platform. The ...
Keytruda, a Merck cancer immunotherapy that has become the world’s top-selling medication, is administered as an intravenous infusion over the course of 30 minutes. The pharmaceutical giant now has ...
Hyaluronic acid injections have been alleged to alter ski jump suit fit and confer an aerodynamic edge. Physicians should be aware of the procedure, risks, and ethical issues.
The FDA has approved a new, simplified monthly subcutaneous (SC) dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; Johnson & Johnson) for the treatment of patients with ...
The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...
The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results